Read Gene

Read Gene Long-term Debt

The Long-Term Debt of Read Gene (RDG.WA) as of Oct 21, 2026 is 8.30 M PLN. In the previous year, Long-Term Debt was 7.91 M PLN — a change of 4.95% (higher).

Long-term Debt

8.30 MPLN

YoY

4.95%

Last updated:

Long-Term Debt of Read Gene is 2025 8.30 M PLN. Long-Term Debt of Read Gene was 2024 7.91 M PLN. It decreases by 4.95% higher compared to the previous year.

The Read Gene Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2016
262,870.00 PLN
Jan 1, 2017
420,780.00 PLN
Jan 1, 2020
4.26 M PLN
Jan 1, 2021
4.86 M PLN
Jan 1, 2022
7.06 M PLN
Jan 1, 2023
7.52 M PLN
Jan 1, 2024
7.91 M PLN
Jan 1, 2025
8.30 M PLN
The Read Gene Long-term Debt history
YEARLong-term DebtYoY
8.30 MPLN+4.95%
7.91 MPLN+5.20%
7.52 MPLN+6.52%
7.06 MPLN+45.13%
4.86 MPLN+14.03%
4.26 MPLN+913.37%
420,780.00PLN+60.07%
262,870.00PLN-63.66%
723,300.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Long-Term Debt of Read Gene is 8.30 M PLN in 2025.

Long-Term Debt of Read Gene changed from 7.91 M PLN to 8.30 M PLN, representing a 4.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Read Gene since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Read Gene

All Key Metrics — Read Gene